GlassScriptPhysician profile
Carmen Janean Salone
NPI 1982347514
$3,677.35
in general payments reported to CMS, 2019-2025
19 companies · $725 in 2025
The $725 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $812 · 2023: $1,070 · 2024: $1,070 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,865.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $501.33 | 2023-2024 | Korlym |
| Teva Pharmaceuticals USA, INC. | $475.36 | 2022-2025 | Austedo Xr, Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $407.53 | 2022-2025 | Xifaxan |
| Novo Nordisk INC | $308.64 | 2022-2025 | |
| Lilly USA, LLC | $307.32 | 2023-2024 | Mounjaro, Zepbound |
| Dexcom, INC. | $204.87 | 2022-2023 | Dexcom G7 Gss (161) |
| Ibsa Pharma INC. | $138.75 | 2022-2023 | Licart |
| Paratek Pharmaceuticals, INC. | $137.45 | 2022-2025 | Nuzyra |
| Abbott Laboratories | $124.98 | 2024 | Freestyle Libre 3 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $124.98 | 2025 | Rexulti |
| Alnylam Pharmaceuticals INC. | $122.91 | 2024 | Amvuttra |
| Takeda Pharmaceuticals U.S.A., INC. | $121.35 | 2025 | Gattex |
| Genzyme Corporation | $120.18 | 2023 | |
| Shield Therapeutics INC | $119.96 | 2023 | Accrufer |
| Abbvie INC. | $112.34 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.92 | 2024 | Jardiance |
| Bioventus LLC | $93.87 | 2022 | |
| Medtronic, INC. | $78.63 | 2023 | Harmony |
| Horizon Therapeutics Plc | $69.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Salone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.